Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Evolocumab After Thrombolysis in Atherosclerotic Acute Ischemic Stroke
ChiCTR2500115300Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of evolocumab in ischemic stroke and brain infarction (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Early Neurological Deterioration (END). Started Dec 2025; status: recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on ChiCTR2500115300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115300.